Quick Answer
Larimar Therapeutics, Inc. reported Operating Income Loss of -$172.50 million for the year ending 2025.
- Larimar Therapeutics, Inc. showed a decrease of -89.8% in Operating Income Loss from 2024 to 2025.
- This data is from Larimar Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2013: -$2.98 million | Q3 2013: -$3.52 million | Q1 2014: -$4.52 million | Q2 2014: -$5.99 million | Q3 2014: -$14.36 million | Q1 2015: -$13.24 million | Q2 2015: -$17.61 million | Q3 2015: -$19.72 million | Q1 2016: -$17.86 million | Q2 2016: -$15.06 million | Q3 2016: -$14.83 million | Q1 2017: -$13.27 million | Q2 2017: -$13.54 million | Q3 2017: -$12.84 million | Q1 2018: -$15.70 million | Q2 2018: -$15.56 million | Q3 2018: -$15.17 million | Q1 2019: -$13.28 million | Q2 2019: -$3.70 million | Q3 2019: -$8.63 million | Q1 2020: -$6.67 million | Q2 2020: -$11.40 million | Q3 2020: -$10.34 million | Q1 2021: -$12.11 million | Q2 2021: -$12.54 million | Q3 2021: -$16.73 million | Q1 2022: -$8.89 million | Q2 2022: -$8.69 million | Q3 2022: -$8.51 million | Q1 2023: -$7.64 million | Q2 2023: -$9.62 million | Q3 2023: -$10.34 million | Q1 2024: -$16.73 million | Q2 2024: -$24.60 million | Q3 2024: -$18.26 million | Q1 2025: -$31.19 million | Q2 2025: -$27.79 million | Q3 2025: -$49.50 million.
- Over the full 14 years of available data (2012 to 2025), Larimar Therapeutics, Inc.'s Operating Income Loss has declined by 1,150.8%.
- Historical annual values: Fiscal year 2025: -$172.50 million | Fiscal year 2024: -$90.89 million | Fiscal year 2023: -$41.76 million | Fiscal year 2022: -$36.53 million | Fiscal year 2021: -$50.47 million | Fiscal year 2020: -$42.80 million | Fiscal year 2019: -$23.21 million | Fiscal year 2018: -$61.12 million | Fiscal year 2017: -$53.00 million | Fiscal year 2016: -$58.23 million | Fiscal year 2015: -$73.81 million | Fiscal year 2014: -$35.53 million | Fiscal year 2013: -$13.78 million | Fiscal year 2012: -$13.79 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: